Atrial Fibrillation General Registry

Atrial Fibrillation Clinical Trial

— AFGenLT  

Official title:

Atrial Fibrillation General Long Term Registry

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02518984
• Other study ID #: AFGen Long Term
• Status: Completed
• Start date: October 2013
• Est. completion date: December 2019

Study information

• Verified date: May 2020
• Source: European Society of Cardiology
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational [Patient Registry]

Clinical Trial Summary

Given the advances in Atrial Fibrillation (AF) management and the availability of new European Society of Cardiology (ESC) guidelines, there is a need for the systematic collection of contemporary data regarding the management and treatment of AF in the member ESC countries. It is now nearly 10 years since the last European registry of AF management was undertaken (as part of the ESC Euro Heart Survey programme), and a new registry was needed.

Description:

Given the advances in Atrial Fibrillation (AF) management and the availability of new European Society of Cardiology (ESC) guidelines, there is a need for the systematic collection of contemporary data regarding the management and treatment of AF in the member ESC countries. It is now nearly 10 years since the last European registry of AF management was undertaken (as part of the ESC Euro Heart Survey programme), and a new registry was needed.

New guidelines on the management of AF have recently been published by the ESC, but it remains unclear how often clinicians adhere to them. Since the last Euro Heart survey, a change in management strategy has necessitated an update on prevalent management practices in AF. This is influenced by clinical availability of catheter ablation as a routine procedure and new antiarrhythmic drugs, and also by developments in stroke thromboprophylaxis and medical therapy options. Under the EURObservational Research Programme (EORP), an AF ablation sentinel pilot registry was launched in 2010.

A survey of AF management under the EORP programme will enable a timely assessment of the uptake of the new ESC guidelines, allow monitoring of implementation and uptake of catheter ablation, new antithrombotic drugs and new antiarrhythmic agents, and will inform about outcomes related to guideline-adherent management of AF.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 19754
• Est. completion date: December 2019
• Est. primary completion date: August 2019
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Patients will be officially enrolled in the study only if ECG diagnosis of AF has been made.

• The qualifying episode of AF should have occurred within one year before the date of baseline.

• AF is the primary or secondary diagnosis, i.e. the current admission / visit may be due to other reasons.

• Patients need not be in AF at the time of enrolment.

• Signed Patient Inform Consent if applicable.

Exclusion Criteria:

• No ECG/Holter with AF recorded.

• Only atrial flutter recorded.

• The qualifying episode of AF occurred more than one year before the date of baseline.

• Age <18 years.

• Patients are already included in the ESC Atrial Fibrillation Long-Term registry if your centre was enrolled in the Pilot phase.

• Patients who are currently or are planned to be taking part in a cardiac clinical trial.

Related Conditions & MeSH terms

• Atrial Fibrillation

Locations

Country	Name	City	State
France	European Society of Cardiology	Biot

Sponsors (1)

Lead Sponsor	Collaborator
European Society of Cardiology

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	vital status		one year follow-up
Other	vital status		two year follow-up
Other	vital status		three year follow-up
Primary	vital status		Baseline